"The patents come at a time when the company is gaining traction. RenovoRx is seeing early adoption of its catheter in select centers across the US, and the RenovoCath has delivered promising results in procedures tackling difficult to treat diseases, including pelvic vein congestion, adenocarcinoma of the pancreas, and liver cancer," says Shaun Bagai, the company's CEO.
According to Dr. David C. Madoff, Professor of Radiology and Vice Chairman for Academic Affairs at Weill Cornell Medicine and RenovoRx advisory board member, the RenovoCath allowed him to successfully treat a patient he might otherwise not have been able to help: "This case, a 5cm solitary transitional cell carcinoma liver metastasis, was one where the numerous vessels feeding the tumor were so small that performing particle embolization with standard microcatheter technology proved difficult. I subsequently performed conventional TACE via the RenovoCath and the results by imaging were remarkable. I believe treating this patient effectively from a transarterial approach would have been impossible without this catheter."
RenovoRx (www.renovorx.com) is developing innovative solutions for the isolation of blood flow and delivery of fluids, including diagnostic materials and therapeutic agents, to selected sites in the peripheral vascular system. The ability to deliver these materials at high concentration to specific vasculature, safely and without perfusion overlap to other regions, is a central paradigm of the company's technology. RenovoRx is based in Silicon Valley, California, and its top financial backers include Astia Angels, Golden Seeds, Sand Hill Angels, The Angels' Forum, The Halo Fund III, L.P., Plug and Play, and Rising Tide Fund/Portfolia.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/renovorx-announces-the-us-patent-and-trademark-office-issuance-of-two-patents-300344213.html